Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

Meir Schechter, Stephen D Wiviott, Itamar Raz, Erica L Goodrich, Aliza Rozenberg, Ilan Yanuv, Sabina A Murphy, Thomas A Zelniker, Martin Fredriksson, Peter A Johansson, Lawrence A Leiter, Deepak L Bhatt, Darren K McGuire, John P H Wilding, Ingrid A M Gause-Nilsson, Avivit Cahn, Anna Maria Langkilde, Marc S Sabatine, Ofri Mosenzon

Open source

DOI: 10.1016/s2213-8587(23)00009-8
Published: 2023-04
Container: The Lancet Diabetes & Endocrinology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-8587-23-00009-8,
  title = {Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial},
  author = {Meir Schechter and Stephen D Wiviott and Itamar Raz and Erica L Goodrich and Aliza Rozenberg and Ilan Yanuv and Sabina A Murphy and Thomas A Zelniker and Martin Fredriksson and Peter A Johansson and Lawrence A Leiter and Deepak L Bhatt and Darren K McGuire and John P H Wilding and Ingrid A M Gause-Nilsson and Avivit Cahn and Anna Maria Langkilde and Marc S Sabatine and Ofri Mosenzon},
  year = {2023},
  journal = {The Lancet Diabetes \&amp; Endocrinology},
  doi = {10.1016/s2213-8587(23)00009-8},
  url = {https://doi.org/10.1016/s2213-8587(23)00009-8}
}

RIS

TY  - JOUR
TI  - Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
AU  - Meir Schechter
AU  - Stephen D Wiviott
AU  - Itamar Raz
AU  - Erica L Goodrich
AU  - Aliza Rozenberg
AU  - Ilan Yanuv
AU  - Sabina A Murphy
AU  - Thomas A Zelniker
AU  - Martin Fredriksson
AU  - Peter A Johansson
AU  - Lawrence A Leiter
AU  - Deepak L Bhatt
AU  - Darren K McGuire
AU  - John P H Wilding
AU  - Ingrid A M Gause-Nilsson
AU  - Avivit Cahn
AU  - Anna Maria Langkilde
AU  - Marc S Sabatine
AU  - Ofri Mosenzon
PY  - 2023
JO  - The Lancet Diabetes &amp; Endocrinology
DO  - 10.1016/s2213-8587(23)00009-8
UR  - https://doi.org/10.1016/s2213-8587(23)00009-8
ER  -

APA

Schechter, M., Wiviott, S. D., Raz, I., Goodrich, E. L., Rozenberg, A., Yanuv, I., Murphy, S. A., Zelniker, T. A., Fredriksson, M., Johansson, P. A., Leiter, L. A., Bhatt, D. L., McGuire, D. K., Wilding, J. P. H., Gause-Nilsson, I. A. M., Cahn, A., Langkilde, A. M., Sabatine, M. S., & Mosenzon, O. (2023). Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(23)00009-8

Source records

crossref · retrieved 2026-09-26T21:04:23.155Z